vastwow.blogg.se - Another word for committed to company

ANOTHER WORD FOR COMMITTED TO COMPANY TRIAL

In consideration of Scope 1, 2 & 3 GHG emissions, BMS realized an 8.2% reduction compared to 2021. Through 2022, BMS has diverted ~83.5% of our waste from landfill. Reduced its environmental footprint: The company made meaningful progress across its environmental commitments.The company remains committed to expanding and maintaining its spend. Advanced supplier diversity: The company spent over $1 billion with suppliers globally who are owned by underrepresented groups, women, veterans, LGBTQ+, people with disabilities and other diverse populations.Increased access for underserved communities: The company launched a new cross-functional team focused on addressing the unique challenges faced by Lower- and Middle-Income Countries (LMICs), which account for 80% of the global population.

ANOTHER WORD FOR COMMITTED TO COMPANY TRIAL

Its efforts to improve clinical trial diversity were recognized in 2022 with a Gold Badge rating on the Bioethics International Scorecard. Addressed barriers to health equity by expanding clinical trial diversity: Bristol Myers Squibb embedded 58% of clinical trial sites into some of the most racially and ethnically diverse metro regions in the United States, surpassing its initial goal of 25% three years earlier than expected.Progressed its global inclusion and diversity and health equity goals: Bristol Myers Squibb awarded nearly $100 million since 2020 across 481 grants reaching over 10 million people, further progressing its commitment to $150 million by 2025.

Further developed its pipeline of innovative medicines to transform patients' lives: In 2022 alone, the company obtained 18 approvals for new medicines, additional indications, and formulations of currently marketed medicines in major markets.

The results of the assessment will inform future updates to the Company’s ESG priorities to better maximize and measure the impact. “I am immensely proud of the progress our teams have made toward achieving our ESG goals and am confident in the positive impact BMS will continue to have on our patients and the world.”Įarlier this year, Bristol Myers Squibb conducted a global double ESG materiality assessment to understand evolving stakeholder views and ensure its ESG strategy reflects the rapidly changing landscape. “At Bristol Myers Squibb, we recognize ESG’s importance to the health and longevity of our business, including how a strong ESG program can improve risk management and support long-term value creation,” said Giovanni Caforio, Chief Executive Officer, Bristol Myers Squibb. The Company’s ESG strategy is embedded in its mission and builds on a legacy of comprehensive and global sustainability efforts that seek to drive business value and positively impact patients, employees, communities, and the planet.

PRINCETON, N.J.-(BUSINESS WIRE)- Bristol Myers Squibb (NYSE: BMY) today published its 2022 Environmental, Social, and Governance (ESG) Report, which details the Company’s goals, strategies, and performance across its four ESG focus areas including ethics, integrity, and quality health equity and access to healthcare global inclusion and diversity and environmental sustainability.Īs a leading biopharmaceutical company, Bristol Myers Squibb is committed to discovering, developing, and delivering innovative medicines that help patients prevail over serious diseases.